Comparison of Chondroitin Sulfate-E Expression in Benign and Malignant Epithelial Type Ovarian Tumors

Kemala Isnainiasih Mantilidewi; Gatot Nyarumenteng A.W.; Andi Kurniadi; Dodi Suardi; Ali Budi Harsono; Siti Salima; Aditiyono A; Kartika Hapsari; Anglita Yantisetiasti

doi:10.24198/obgynia.v8i2.861

Comparison of Chondroitin Sulfate-E Expression in Benign and Malignant Epithelial Type Ovarian Tumors

Kemala Isnainiasih Mantilidewi, Gatot Nyarumenteng A.W., Andi Kurniadi, Dodi Suardi, Ali Budi Harsono, Siti Salima, Aditiyono A, Kartika Hapsari, Anglita Yantisetiasti

Abstract

Objective: Ovarian cancer is the fifth leading cause of cancer-related death in women, due to late diagnosis and limited screening methods. Chondroitin Sulfate-E (CS-E) has shown potential as biomarkers. This study aims to evaluate CS-E expression in epithelial-type benign and malignant ovarian tumors and its potential as a biomarker using QuPath software.
Methods: This observational analytic study used a cross-sectional design. Samples were selected based on histopathology of patients with epithelial-type benign and malignant ovarian tumors from surgeries in 2023. Immunohistochemistry using the GD3G7 antibody was performed to detect CS-E expression in tumor tissues preserved in paraffin blocks at Dr. Hasan Sadikin General Hospital Bandung. Expression was quantified using QuPath software. Statistical analysis used the Mann-Whitney and t-test.
Result: No significant difference in CS-E expression was found between malignant and benign tumors (p = 0.492). Demographic factors (age, BMI, menopausal status, and parity) showed no significant differences between groups.
Conclusion: CS-E expression has not yet demonstrated potential as a biomarker to distinguish between benign and malignant ovarian tumors.

Perbandingan Ekspresi Chondroitin Sulfate-E pada Tumor Ovarium Jinak dan Ganas Tipe Epitel

Abstrak
Tujuan: Kanker ovarium merupakan penyebab kematian kelima terbanyak terkait kanker pada wanita yang disebabkan oleh keterlambatan diagnosis dan keterbatasan metode skrining. Chondroitin Sulfate-E (CS-E) menunjukkan potensi sebagai biomarker. Penelitian ini bertujuan mengevaluasi ekspresi CS-E pada tumor ovarium jinak dan ganas tipe epitelial serta menilai potensinya sebagai biomarker menggunakan perangkat lunak QuPath.
Metode: Penelitian analitik observasional ini menggunakan desain potong lintang. Sampel dipilih berdasarkan hasil histopatologi pasien dengan tumor ovarium jinak dan ganas tipe epitelial dari operasi tahun 2023. Pemeriksaan imunohistokimia dengan antibodi GD3G7 dilakukan untuk mendeteksi ekspresi CS-E pada jaringan tumor yang diawetkan dalam blok parafin di RSUP Dr. Hasan Sadikin Bandung. Ekspresi dianalisis secara kuantitatif menggunakan perangkat lunak QuPath. Uji statistik yang digunakan adalah Mann-Whitney dan uji t.
Hasil: Tidak ditemukan perbedaan bermakna dalam ekspresi CS-E antara tumor ganas dan jinak (p = 0,492). Faktor demografis (usia, indeks massa tubuh, status menopause, dan paritas) juga tidak menunjukkan perbedaan bermakna antar kelompok.
Kesimpulan: Ekspresi CS-E belum menunjukkan potensi sebagai biomarker untuk membedakan antara tumor ovarium jinak dan ganas. Kata kunci: Biomarker, GD3G7, Glikosaminoglikan, Kanker Ovarium, Kondroitin sulfat

Keywords

Biomarkers;Chondroitin sulfate;GD3G7;Glycosaminoglycans;Ovarian Cancer

Full Text:

PDF

References

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet [Internet]. 2014;384(9951):1376–88. Available from: http://dx.doi.org/10.1016/S0140-6736(13)62146-7 doi: 10.1016/S0140-6736(13)62146-7

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89. https://doi.org/10.1002/ijc.33588

Liu JH, Zanotti KM. Management of the adnexal mass. Obstet Gynecol. 2011;117(6):1413–28. https://doi.org/10.1097/AOG.0b013e31821c62b6

Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol. 2018;51(3):293–303. https://doi.org/10.1002/uog.17557

Rupa R, Prema R, Popat PB, Manchanda S, Venkatesh K, Chandramohan A, et al. Imaging Recommendations for Diagnosis, Staging, and Management of Ovarian and Fallopian Tube Cancers. Indian J Med Paediatr Oncol. 2023;44(1):100–9. https://doi.org/10.1055/s-0042-1759518

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):1–10. https://doi.org/10.1186/s13048-019-0503-7

Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation. 2002 Dec;70(9–10):537–46. https://doi.org/10.1046/j.1432-0436.2002.700907.x

Vallen MJE, Van Der Steen SCHA, Van Tilborg AAG, Massuger LFAG, Van Kuppevelt TH. Sulfated sugars in the extracellular matrix orchestrate ovarian cancer development: “When sweet turns sour.” Gynecol Oncol [Internet]. 2014;135(2):371–81. Available from: http://dx.doi.org/10.1016/j.ygyno.2014.08.023 doi: 10.1016/j.ygyno.2014.08.023

Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: Key players in cancer cell biology and treatment. FEBS J. 2012;279(7):1177–97. https://doi.org/10.1111/j.1742-4658.2012.08529.x

Braat DDM. Diagnosis and management of ovarian disorders. Eur J Obstet Gynecol Reprod Biol. 1997;72(2):217. https://doi.org/10.1016/s0301-2115(96)02679-6

Vallen MJE, Schmidt S, Oosterhof A, Bulten J, Massuger LFAG, Van Kuppevelt TH. Primary ovarian carcinomas and abdominal metastasis contain 4,6-disulfated chondroitin sulfate rich regions, which provide adhesive properties to tumour cells. PLoS One. 2014;9(11):1–10. https://doi.org/10.1371/journal.pone.0111806

Clinton SK, Giovannucci EL, Hursting SD. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions. J Nutr. 2020;150(4):663–71. https://doi.org/10.1093/jn/nxz268

Rampersad AC, Wang Y, Smith ER, Xu X. Menopause and ovarian cancer risk : mechanisms and experimental support. Am J Clin Exp Obs Gynecol. 2015;2(1):14–23.

Shen F, Chen S, Gao Y, Dai X, Chen Q. The prevalence of malignant and borderline ovarian cancer in pre- and post-menopausal Chinese women. Oncotarget. 2017;8(46):80589–94. https://doi.org/10.18632/oncotarget.20384

Bandera E V., Lee VS, Qin B, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of body mass index on ovarian cancer survival varies by stage. Br J Cancer [Internet]. 2017;117(2):282–9. Available from: http://dx.doi.org/10.1038/bjc.2017.162 doi: 10.1038/bjc.2017.162

Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, et al. Body mass index and risk of ovarian cancer. Cancer. 2009;115(4):812–22. https://doi.org/10.1002/cncr.24086

Beehler GP, Sekhon M, Baker JA, Teter BE, McCann SE, Rodabaugh KJ, et al. Risk of ovarian cancer associated with BMI varies by menopausal status. J Nutr [Internet]. 2006;136(11):2881–6. Available from: https://doi.org/10.1093/jn/136.11.2881 doi: 10.1093/jn/136.11.2881

Gaitskell K, Hermon C, Barnes I, Pirie K, Floud S, Green J, et al. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. Cancer Epidemiol. 2022;76(July 2021):1–8. https://doi.org/10.1016/j.canep.2021.102074

Khalafi-Nezhad A, Ebrahimi V, Ahmadpour F, Momtahan M, Robati M, Saraf Z, et al. Parity as a prognostic factor in patients with advanced-stage epithelial ovarian cancer. Cancer Manag Res. 2020;12:1447–56. https://doi.org/10.2147/CMAR.S237073

Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. Int J Cancer. 2018;142(2):281–9. https://doi.org/10.1002/ijc.31063

Ten Dam GB, Van De Westerlo EMA, Purushothaman A, Stan R V., Bulten J, Sweep FCGJ, et al. Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am J Pathol. 2007;171(4):1324–33. https://doi.org/10.2353/ajpath.2007.070111

Vallen MJE, Massuger LFAG, ten Dam GB, Bulten J, van Kuppevelt TH. Highly sulfated chondroitin sulfates, a novel class of prognostic biomarkers in ovarian cancer tissue. Gynecol Oncol. 2012 Oct;127(1):202–9. https://doi.org/10.1016/j.ygyno.2012.06.022

Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):1–7. https://doi.org/10.1038/s41598-017-17204-5

Hasegawa T, Someya M, Tsuchiya T, Kitagawa M, Fukushima Y, Gocho T, et al. Identification and Quantification of Radiotherapy-related Protein Expression in Cancer Tissues Using the Qupath Software and Prediction of Treatment Response. In Vivo (Brooklyn). 2024;38(3):1470–6. https://doi.org/10.21873/invivo.13593

Catteau X, Zindy E, Bouri S, Noël JC, Salmon I, Decaestecker C. Comparison Between Manual and Automated Assessment of Ki-67 in Breast Carcinoma: Test of a Simple Method in Daily Practice. Technol Cancer Res Treat. 2023;22.

DOI: http://dx.doi.org/10.24198/obgynia.v8i2.861